- Prestigious ALS Association grant awarded to BWH to study the utility of an intranasal anti-CD3 monoclonal antibody in an...
ANNOUNCEMENT NO. 229 15 September 2022 Annual Report 2021/22 (1 July 2021 - 30 June 2022) Strong growth despite challenging...
Company confident to clarify legitimacy of its position and fully cooperating with authoritiesBasel, September 15, 2022 — Novartis today confirms...
- Registrational studies planned to start in 4Q 2022 - - Two-year data from Phase 2a Open Label Extension study...
Follows CDC & World Health Organization's (WHO) announcement that US now meets criteria for country with circulating vaccine-derived poliovirus (cVDPV)Surveillance wastewater and...
NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage...
– Transaction values Apollomics at pre-money equity value of $899 million– Apollomics is a late-stage clinical biopharmaceutical company developing innovative...
AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments...
TOWER ONE CONSTRUCTION UPDATE FOR THE MONTH OF AUGUST 2022VANCOUVER, BC, CANADA , Sept. 14, 2022 (GLOBE NEWSWIRE) -- TOWER...
EDISON, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial...
- Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 -...
SAN DIEGO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a...
CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as...
ASLAN plans to begin TREK-DX (TRials in EblasaKimab in Dupilumab eXperienced AD patients) in the fourth quarter of 2022 to...
BETHLEHEM, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home...
Initiation of the Phase 2 trial is expected in Q4 2022, with top-line data expected in 2H 2023 Company management...
NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
All 3 pemvidutide dosing groups (1.2 mg, 1.8 mg, 2.4 mg) achieved the primary endpoint of relative and absolute reductions...
Data include the persistence of immune responses and protection against variants of concern, especially Delta and OmicronOcugen has North American...
TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...